These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 19384429)
1. Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Tinelli A; Vergara D; Martignago R; Leo G; Malvasi A; Tinelli R; Marsigliante S; Maffia M; Lorusso V Curr Genomics; 2007 Aug; 8(5):335-42. PubMed ID: 19384429 [TBL] [Abstract][Full Text] [Related]
2. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Tinelli A; Vergara D; Martignago R; Leo G; Pisanò M; Malvasi A Curr Genomics; 2009 Jun; 10(4):240-9. PubMed ID: 19949545 [TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma. Rabjerg M Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890 [TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies. Leung F; Diamandis EP; Kulasingam V Adv Clin Chem; 2014; 66():25-77. PubMed ID: 25344985 [TBL] [Abstract][Full Text] [Related]
5. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics. Phan JH; Quo CF; Wang MD Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692 [TBL] [Abstract][Full Text] [Related]
6. Proteomics biomarkers for solid tumors: Current status and future prospects. Belczacka I; Latosinska A; Metzger J; Marx D; Vlahou A; Mischak H; Frantzi M Mass Spectrom Rev; 2019 Jan; 38(1):49-78. PubMed ID: 29889308 [TBL] [Abstract][Full Text] [Related]
7. New perspectives in diagnosis of gynaecological cancers: Emerging role of circulating microRNAs as novel biomarkers. Zavesky L; Jandakova E; Turyna R; Langmeierova L; Weinberger V; Minar L; Kohoutova M Neoplasma; 2015; 62(4):509-20. PubMed ID: 25997972 [TBL] [Abstract][Full Text] [Related]
8. An overview of biomarkers for the ovarian cancer diagnosis. Zhang B; Cai FF; Zhong XY Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171 [TBL] [Abstract][Full Text] [Related]
9. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Leung F; Diamandis EP; Kulasingam V Biomark Med; 2012 Oct; 6(5):613-25. PubMed ID: 23075239 [TBL] [Abstract][Full Text] [Related]
10. Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics. Vergara D; Tinelli A; Martignago R; Malvasi A; Chiuri VE; Leo G Curr Cancer Drug Targets; 2010 Feb; 10(1):107-16. PubMed ID: 20088785 [TBL] [Abstract][Full Text] [Related]
16. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y Expert Rev Proteomics; 2016 Oct; 13(10):905-915. PubMed ID: 27598304 [TBL] [Abstract][Full Text] [Related]
17. Status of Immune Oncology: Challenges and Opportunities. Cesano A; Marincola FM; Thurin M Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145 [TBL] [Abstract][Full Text] [Related]